Anaplastic astrocytoma market forecast to reach $0.64B by 2030 at 7% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Anaplastic Astrocytoma Market Grow Between 2026 And 2030?

The anaplastic astrocytoma market has experienced substantial expansion in recent years. Its value is forecast to increase from $0.46 billion in 2025 to $0.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.1%. The growth observed historically can be attributed to enhancements in brain tumor diagnostics, the availability of neurosurgical treatment options, the proliferation of oncology treatment centers, rising engagement in clinical trials, and the increased application of radiotherapy.

The anaplastic astrocytoma market is projected to experience substantial expansion in the coming years, with its size anticipated to reach $0.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is primarily driven by increasing investments in neuro-oncology research, the rising adoption of precision medicine approaches, the expansion of targeted and adjunct therapies, a growing focus on early detection strategies, and increased collaboration between research institutions. Significant trends expected in the forecast period include the increasing adoption of multimodal treatment approaches, a rising use of advanced neuroimaging tools, a growing focus on personalized oncology therapies, the expansion of clinical research activities, and enhanced integration of surgical and radiotherapy protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

What Leading Drivers Are Supporting The Anaplastic Astrocytoma Market Expansion?

The increasing occurrence of both primary malignant and non-malignant brain tumors is anticipated to propel the expansion of the anaplastic astrocytoma market. Brain tumors are growths found in the brain, classified as either cancerous (malignant) and invasive, or non-cancerous (benign) and non-invasive, presenting varying degrees of aggressiveness and potential to spread. The anaplastic astrocytoma treatment focuses on removing the tumor and surrounding impacted tissue while aiming to preserve brain function. For instance, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based non-profit organization, reported that around 24,810 adults in the United States were expected to be diagnosed with primary cancerous tumors originating in the brain and spinal cord, with 14,280 cases affecting men and 10,530 women. Consequently, the rising incidence of primary malignant and non-malignant brain tumors will drive the growth of the anaplastic astrocytoma market moving forward.

How Are Different Segments Classified In The Anaplastic Astrocytoma Market Segment Analysis?

The anaplastic astrocytoma market covered in this report is segmented –

1) By Treatment Type: Surgery, Chemotherapy, Radiation Therapy

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Specialty Cancer Centers

Subsegments:

1) By Surgery: Maximal Safe Tumor Resection, Stereotactic Biopsy

2) By Chemotherapy: Alkylating Agents, Targeted Therapy

3) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT)

What Emerging Trends Are Seen In The Anaplastic Astrocytoma Market?

Companies operating within the anaplastic astrocytoma market are concentrating on developing sophisticated combination therapies to improve both overall survival and progression-free survival for patients with recurrent disease. This approach involves using two or more drugs simultaneously to target cancer pathways, thereby boosting treatment efficacy and decelerating tumor progression. For example, in November 2024, Orbus Therapeutics, a US-based biopharmaceutical company, introduced a combination of eflornithine and lomustine in its Phase 3 STELLAR study. The therapy has shown clinically significant improvements in overall survival and progression-free survival for individuals with grade 3 IDH mutant astrocytoma. Its key attributes feature a median overall survival of 34.9 months, compared to 23.5 months with lomustine alone, a median progression-free survival of 15.8 months versus 7.2 months, and a generally tolerable safety profile. The treatment’s mechanism relies on eflornithine’s ability to irreversibly inhibit ornithine decarboxylase, a crucial enzyme in polyamine biosynthesis, which enhances its cytostatic effect. The study, which included over 343 patients across North America and Europe, revealed substantial clinical advantages in a patient population that is typically difficult to treat, offering a promising new choice for patients suffering from recurrent anaplastic astrocytoma.

Who Are The Companies Driving Activity In The Anaplastic Astrocytoma Market?

Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Eisai Co. Ltd, AbbVie Inc., Bayer AG, Amgen Inc., Ipsen SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., Novocure Ltd., Celldex Therapeutics Inc.

Get The Full Anaplastic Astrocytoma Market Report:

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

Which Region Leads The Anaplastic Astrocytoma Market In Overall Market Size?

North America was the largest region in the anaplastic astrocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaplastic astrocytoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anaplastic Astrocytoma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

Browse Through More Reports Similar to the Global Anaplastic Astrocytoma Market 2026, By The Business Research Company

Paraganglioma Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Anaplastic Astrocytoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

Anaplastic Astrocytoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795